VU 0422288

Pricing Availability   Qty
说明: Selective positive allosteric modulator of group III mGlu receptors
别名: ML 396
化学名: N-[3-Chloro-4-[(5-chloro-2-pyridinyl)oxy]phenyl]-2-pyridinecarboxamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (3)

生物活性 for VU 0422288

VU 0422288 is a group III mGlu receptor positive allosteric modulator (EC50 values are 108, 125 and 146 nM for mGlu4, mGlu8 and mGlu7 respectively). Exhibits selectivity over a panel of 68 other GPCRs, ion channels and transporters. Potentiates mGlu7-mediated reductions in excitatory post synaptic potentials in hippocampal slices.

技术数据 for VU 0422288

分子量 360.19
公式 C17H11Cl2N3O2
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 1630936-95-6
PubChem ID 73058507
InChI Key MZRLPXFGQKQHST-UHFFFAOYSA-N
Smiles ClC1=CC(NC(C3=CC=CC=N3)=O)=CC=C1OC2=CC=C(Cl)C=N2

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for VU 0422288

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 36.02 100

制备储备液 for VU 0422288

以下数据基于产品分子量 360.19。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.78 mL 13.88 mL 27.76 mL
5 mM 0.56 mL 2.78 mL 5.55 mL
10 mM 0.28 mL 1.39 mL 2.78 mL
50 mM 0.06 mL 0.28 mL 0.56 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for VU 0422288

参考文献是支持产品生物活性的出版物。

Jalan-Sakrikar et al (2014) Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem.Neurosci. 5 1221 PMID: 25225882


If you know of a relevant reference for VU 0422288, please let us know.

关键词: VU 0422288, VU 0422288 supplier, VU0422288, ML396, groupIII, mglu4, mglu8, mglu7, metabotropic, receptors, positive, allosteric, modulators, selective, PAM, ML, 396, Glutamate, (Metabotropic), Group, III, Receptors, 5378, Tocris Bioscience

篇 VU 0422288 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 VU 0422288 的引用文献。 您是否知道使用了 Tocris VU 0422288 的优秀论文? 请告知我们.

VU 0422288 的评论

目前没有该产品的评论。 Be the first to review VU 0422288 and earn rewards!

Have you used VU 0422288?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.